ArticleFrontiers in veterinary science2026
Development and immunogenicity of a novel subunit vaccine candidate against avian metapneumovirus.
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: aMPV subtype B remains one of the major respiratory pathogens affecting commercial poultry worldwide despite the widespread implementation of vaccination programs. In the present study, epidemiological surveillance, virus isolation, and immunogenic evaluation of a newly developed subunit vaccine against aMPV subtype B were conducted. Methods: Clinical samples, representing 115 chicken flocks from 16 commercial poultry farms located in three regions of Kazakhstan, were screened for aMPV subtype B using multiplex real-time RT-PCR. Approximately 20% of the samples collected during the spring season tested positive for aMPV, with subtype B predominating among the detected strains. Phylogenetic analysis revealed that the identified viruses clustered within subtype B and were closely related to vaccine-like strains while forming a distinct monophyletic group.For virus isolation, field samples that tested negative for IBV, NDV, ILTV, and Results: The immunogenicity of the vaccine was evaluated in chickens following a prime-boost immunization regimen and compared with that of a commercial live vaccine. The subunit vaccine induced 100% seroconversion by day 14 post-vaccination and elicited significantly higher IgG and virus-neutralizing antibody titers than the live vaccine. Neutralizing antibody titers were 8-fold higher after primary immunization and 16-fold higher after booster immunization compared with those in the live vaccine group. Furthermore, the subunit vaccine significantly enhanced the expression of IFN-γ and IL-4, indicating activation of both Th1- and Th2-mediated immune responses. Conclusion: Overall, these findings demonstrate that the developed subunit vaccine induces robust and durable humoral and cellular immune responses and represents a promising candidate for the prevention and control of aMPV subtype B infection in poultry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.